Autopsy report · NCT03579160
Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes
Cause of deathFunding or business, also slow enrollment
“Due to the insufficient accrual rate and strategic reasons to focus our efforts on higher impact research projects.”
Life of this trial
- Registered 7 months before it started.
- Ran for about 3 years before it stopped.
- 10 participants enrolled.
- Results were posted on the registry 4 years 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- Brigham and Women's Hospital
- Sponsor type
- University, hospital or other
- Conditions
- Wound of Skin; Wound Heal; Surgical Wound; Full Thickness Skin Graft Healing
- Interventions
- 0.25% timolol gel with full-thickness skin grafts; Vaseline dressing
- Participants
- 10
- Sites
- 1
- Countries
- United States
Trials that died the same way
- RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry
“due to Sponsor's ongoing and upcoming projects and overall research priorities” - Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies
“Lack of funding and change in research direction.” - Prospective Study of Functional and Quality of Life Outcomes in Panniculectomy Patients
“Due to complexity and cost of study (no outside funding)” - Diazoxide Suppression Test P&F Study
“Reprioritization of research efforts” - Postoperative Antibiotics Following Primary and Secondary Breast Augmentation
“Do not have adequate funding to proceed with project.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.